Nanjing, June 6, 2024 / US Newswire / - Recently, the Shenzhen Stock Exchange held a theme week event for the 2023 Shenzhen Stock Market Performance Explanation Meeting. More than 40 high-quality listed companies in the Shenzhen market communicated deeply with investors through the combination of "online + offline". As a domestic high-quality development enterprise of medical devices, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. participated in the theme performance briefing of "Advanced Manufacturing Creates the Future", and Chairman Wu Qun of Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. gave a comprehensive and multi-dimensional interpretation of the company's performance, operating conditions, and development strategy to investors. He also answered key concerns.
In 2023, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. achieved revenue of RMB 7.972 billion and net income attributable to the parent company of RMB 2.396 billion, making it the second largest medical device company in China in terms of revenue. Looking back on the development history of the company, "advanced manufacturing" has provided a continuous source of power for the high-quality development of Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Since its establishment in 1998, the company has established 9 large production bases, among which the global industrial base of Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. has adopted the industrial 4.0 and intelligent manufacturing standards, creating an intelligent collaborative production system integrating CNAS national product laboratory, intelligent manufacturing factory, digital workshop, etc., integrating the supply chain end and production integration, promoting Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. to become one of the largest medical device companies in China in terms of scale, leading in manufacturing technology, efficiency, and digitization, and has been recognized as a "National High-tech Enterprise " by the Ministry of Science and Technology Torch Center.
Chairman Wu Qun of Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. introduced at the briefing that the company closely focuses on market demand and technological progress, actively explores new production processes and manufacturing models, continuously improves the level of production automation and intelligence, and is committed to becoming a benchmark enterprise in the field of medical devices in China. In the future, the company will continue to regard innovation as the driving force for development, continuously attach importance to research and development investment, adhere to scientific and technological innovation, and shape new driving forces and new advantages for the company's development.
In recent years, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. has taken "innovation to reshape medical devices" as its development strategy, attached great importance to the incubation of China's "smart" manufacturing, increased research and development investment, strengthened the core of innovation, and created independent research and development capabilities. It has established 12 major research and development centers and continued to carry out scientific research on industry key and difficult technical issues. Through independent research and development and mergers and acquisitions, it has completed the refinement and expansion of the business map, with more than 600 product categories, many of which represent the latest achievements in the world's cutting-edge technology fields, laying a solid foundation for China's "smart" manufacturing to enter the world stage.
Through continuous deep cultivation of advanced manufacturing and research and development innovation, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. has achieved continuous growth in revenue scale since it went public for 16 consecutive years, becoming a representative of high-quality development of Enterprises in the Shenzhen Stock Exchange and becoming a premium target for investors to practice value investment and long-term investment in the capital market. In addition, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. has always adhered to the advanced dividend policy to give back to investors. Since going public, the total amount of dividends has reached RMB 3.392 billion (excluding share buybacks), exceeding the total amount of fundraising since the listing. Driven by the improvement of performance quality and investor returns, the company's stock price has recently reached a new high in nine years, and its market value has exceeded RMB 40 billion.
At the performance briefing, Chairman Wu Qun of Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. gave a detailed answer to investors' key concerns. Regarding the company's future development strategy, Wu Qun stated that focus and concentration will become the strategic keywords for the company in the next few years. As the company continues to grow in size, it needs to cultivate the ability to simplify complex issues by training internal teams. This means that the company will continue to deepen its cultivation in the three core arenas of respiratory and oxygen therapy, blood glucose and POCT, and disinfection and infection control, and strengthen the comprehensive strength of its advantageous sectors.
As the industry matures, it is imperative to expand overseas markets. In 2023, the company achieved 64 overseas registrations and certifications, accelerating its expansion to the global market. Wu Qun stated that in the future, the company will adhere to the long-term mainstay and, based on the differences in medical demand, economic level, cultural background and other factors of different countries and regions, drive the continued growth of the company's overseas business through multiple measures such as promoting the landing of overseas registration and certification, improving the construction of overseas localization teams, expanding export channels and enhancing brand influence. Overall, the opportunities abroad are much greater than the challenges. With the landing of overseas registrations, the market will have great potential in the future. The company hopes to continue to increase the share of its own brand in overseas business, which may be slow at present, but is being carried out in a practical manner.
Regarding the 2024 business development plan, Jiangsu Yuyue Medical Equipment & Supply will continue to follow the "innovative reshaping of medical instruments" strategy, with the core business philosophy that revolves around the consumer. Building on the foundation of cornerstone businesses such as blood pressure testing, temperature testing, traditional Chinese medicine devices, and surgical equipment, the strategic layout will shift from defense to offense and from mature assets to growth businesses. The company will continue to release new products for the respiratory and oxygen supply, blood sugar and POCT, disinfection and infection control, and other core racetracks through self-research and mergers and acquisitions, in order to drive innovation and continuously improve health management programs. This will promote the vigorous development of the company's business scale and create more value for investors and society.